Your doctor may soon recommend adding a simple, inexpensive pill to your cancer treatment plan — and it is not a new chemotherapy drug or an immunotherapy breakthrough. It is aspirin. Recent landmark clinical trials, most notably the ALASCCA trial published in the New England Journal of Medicine in 2025, have shown that 160 mg of daily aspirin reduced the risk of colorectal cancer recurrence by 51% in patients whose tumors carry specific PI3K pathway mutations. For roughly 30% of colorectal cancer patients who harbor these genetic alterations, low-dose aspirin after standard treatment cut recurrence rates from 14.1% down to 7.7% — a meaningful difference that has oncologists rethinking the role of this century-old medication. But this is not a blanket recommendation, and the story is more complicated than a single headline.
Aspirin did not help patients with colorectal liver metastases in the ASAC trial, and a major follow-up study in healthy older adults found no reduction in overall cancer incidence. The evidence points firmly in one direction: aspirin works best when matched to the right patient, with the right tumor genetics, at the right stage of disease. This article covers the landmark trials driving the shift, the biomarkers your oncologist may test for, who should not take aspirin for cancer, and what all of this means for patients navigating treatment decisions — particularly those also managing cognitive health and dementia risk. The intersection of cancer treatment and brain health matters more than many people realize. Patients with cancer, especially older adults, face heightened risks of cognitive decline during and after treatment. Any addition to a treatment regimen — including aspirin, which carries its own bleeding risks — needs to be weighed carefully in the context of total brain and body health.
Table of Contents
- What Clinical Evidence Supports Adding Low-Dose Aspirin to Cancer Treatment?
- How Does Aspirin Actually Fight Cancer at the Cellular Level?
- The ASPREE Surprise — Why Aspirin Did Not Help Healthy Older Adults Prevent Cancer
- Who Should Talk to Their Doctor About Aspirin and Cancer — And Who Should Not
- The Role of Biomarkers and Personalized Medicine in Aspirin Decisions
- What This Means for Patients Managing Both Cancer and Cognitive Health
- Where the Research Goes From Here
- Conclusion
- Frequently Asked Questions
What Clinical Evidence Supports Adding Low-Dose Aspirin to Cancer Treatment?
The strongest evidence comes from two major randomized controlled trials that reported results in 2025. The ALASCCA trial, conducted across multiple centers in Sweden and Europe, was a double-blind, placebo-controlled study that enrolled colorectal cancer patients whose tumors harbored PI3K pathway mutations. Patients who took 160 mg of aspirin daily after completing standard treatment saw recurrence rates of just 7.7%, compared to 14.1% in the placebo group. Among those with PIK3CA hotspot mutations in exon 9 or exon 20 specifically, the risk reduction reached 51%. These are not marginal numbers. For context, many targeted cancer therapies that cost tens of thousands of dollars per month deliver comparable or smaller reductions in recurrence risk.
The ASCOLT trial, an international phase 3 study with over 1,500 patients, reinforced these findings. Aspirin demonstrated superior disease-free survival with a hazard ratio of 0.70, and among patients with PI3K mutations, the hazard ratio dropped to 0.56 — meaning a 44% reduction in recurrence risk. Together, these two trials represent the most robust evidence to date that aspirin has a legitimate place in adjuvant cancer treatment, at least for a genetically defined subset of colorectal cancer patients. What makes these results particularly compelling is that they came from rigorous, randomized, placebo-controlled designs — the gold standard in clinical research. Earlier observational studies had hinted at aspirin’s anticancer potential for years, but oncologists rightly hesitated to act on correlational data alone. The ALASCCA and ASCOLT trials changed that calculus.
How Does Aspirin Actually Fight Cancer at the Cellular Level?
Aspirin’s anticancer mechanisms are not fully mapped, but researchers have identified several plausible pathways. A March 2025 study reported by ScienceDaily found that scientists discovered how aspirin could prevent some cancers from spreading, shedding new light on its anti-metastatic properties. Aspirin appears to interfere with the inflammatory signaling that tumors exploit to grow, invade surrounding tissue, and establish themselves in distant organs. Chronic inflammation has long been recognized as a driver of cancer progression, and aspirin’s well-known anti-inflammatory effects may directly disrupt this process. The PI3K pathway connection adds a more specific layer to the story. PI3K pathway mutations, found in approximately 30% of colorectal cancers, drive cell growth and survival signaling.
Aspirin appears to interact with this pathway in ways that make mutated cells more vulnerable — though the precise molecular details are still being worked out. However, if your tumor does not carry a PI3K mutation, the current evidence does not support expecting the same benefit. This distinction is critical: aspirin is not acting as a general anticancer agent in these trials but rather exploiting a specific molecular vulnerability. It is also worth noting that aspirin’s effects on platelets — the blood cells involved in clotting — may play a role. Platelets can shield circulating tumor cells from immune detection, and aspirin’s antiplatelet activity could strip away that protective cover. This mechanism would help explain why aspirin seems to reduce metastatic spread rather than shrinking existing tumors.
The ASPREE Surprise — Why Aspirin Did Not Help Healthy Older Adults Prevent Cancer
Not every aspirin-cancer study has delivered good news. The ASPREE trial follow-up, published in JAMA Oncology in January 2026 by researchers at Monash University, examined healthy adults aged 70 and older who took daily low-dose aspirin for primary prevention — that is, to prevent cancer before it ever developed. The results were sobering: no reduction in overall cancer incidence, and a 15% increase in cancer-related mortality was observed during the active intervention period. That mortality finding understandably alarmed many patients and clinicians. However, the elevated risk did not persist into the post-trial follow-up period, suggesting there was no lasting harmful effect from the aspirin itself.
Researchers have speculated that aspirin may have interfered with immune surveillance in ways that allowed existing but undetected cancers to progress more quickly, but this remains a hypothesis rather than a settled explanation. The ASPREE results carry an important lesson for patients and caregivers in the dementia space. Many older adults already take aspirin for cardiovascular protection, and the instinct to add cancer prevention to the list of reasons might feel logical. But the data say otherwise for healthy older adults without a specific cancer diagnosis or genetic risk factor. This is a case where more is not better, and where the decision to take aspirin must be individualized based on actual risk factors rather than a general hope of benefit.
Who Should Talk to Their Doctor About Aspirin and Cancer — And Who Should Not
The patients most likely to benefit from adding low-dose aspirin to cancer treatment are those with colorectal cancer whose tumors harbor PI3K pathway mutations. If you or a loved one has been diagnosed with colorectal cancer, asking your oncologist whether PI3K mutation testing was performed on the tumor sample is a reasonable and important step. Not all pathology reports include this information by default, and the ALASCCA trial results may not yet be reflected in every oncologist’s treatment protocols. Patients with Lynch syndrome — a hereditary condition that dramatically increases colorectal cancer risk — represent another group with strong evidence behind aspirin use. The CAPP2 study, published in The Lancet, showed that aspirin reduced cancer incidence in Lynch syndrome patients over 10 to 20 years of follow-up.
For families affected by Lynch syndrome, this is a conversation worth having at the earliest opportunity. On the other hand, the ASAC trial delivered a clear warning: aspirin did not improve disease-free or overall survival for patients who had undergone complete surgical removal of colorectal cancer liver metastases, and it was associated with increased serious adverse events in that population. This finding highlights a genuine tradeoff. Aspirin is not harmless, and applying it in the wrong clinical context can cause net harm. The main risk is gastrointestinal bleeding. In the ALASCCA trial, severe side effects were rare — one case of severe GI bleeding, one case of brain bleeding, and one allergic reaction — but these risks scale differently in patients who are already medically fragile from surgery or advanced disease.
The Role of Biomarkers and Personalized Medicine in Aspirin Decisions
One of the most promising developments in this area is the identification of clonal hematopoiesis of indeterminate potential, or CHIP, as a biomarker that may predict who benefits most from daily low-dose aspirin for cancer prevention. CHIP is a condition in which blood stem cells acquire mutations that give them a growth advantage, leading to expanded populations of mutant blood cells. Research has identified CHIP as the strongest predictor of whether daily low-dose aspirin could help prevent cancer in healthy older adults — pointing squarely toward a personalized medicine approach rather than population-wide recommendations. This matters for patients concerned about both cancer and cognitive decline, because CHIP has also been linked to increased cardiovascular disease risk and potentially to neuroinflammation. A future in which a single blood test could help determine whether aspirin is likely to help or hurt a given patient — across cancer, heart disease, and possibly brain health endpoints — is not as distant as it might sound. However, CHIP testing is not yet part of routine clinical practice, and there are no formal guidelines incorporating it into aspirin prescribing decisions.
Patients should be cautious about over-interpreting early research. The broader lesson is that the era of one-size-fits-all aspirin recommendations is ending. The U.S. Preventive Services Task Force has found that low-dose aspirin can reduce colorectal cancer risk by up to 40% in people who meet specific criteria, and a 2020 meta-analysis reported a 27% reduced colorectal cancer risk in regular aspirin users. But achieving the full cancer-prevention benefit requires at least 10 years of consistent use, according to both the USPSTF and the American College of Gastroenterology. For older adults already living with dementia or significant comorbidities, a decade-long aspirin commitment is a different proposition than it is for a 50-year-old with a strong family history of colon cancer.
What This Means for Patients Managing Both Cancer and Cognitive Health
Cancer treatment itself can take a toll on cognitive function — a phenomenon often called “chemo brain” that overlaps uncomfortably with the cognitive concerns of older adults already at risk for dementia. Adding any medication to a treatment regimen requires evaluating its effects on the whole patient, not just the tumor. Aspirin’s antiplatelet effects, while potentially beneficial against cancer spread, also increase the risk of bleeding events including intracranial hemorrhage, which can cause lasting cognitive damage.
For caregivers helping a loved one navigate a cancer diagnosis alongside dementia or mild cognitive impairment, the practical takeaway is this: ask the oncology team specifically whether PI3K pathway testing has been done, whether aspirin is being considered, and how bleeding risk has been assessed given the patient’s full medical picture. Do not start aspirin on your own based on trial headlines. The benefit is real but narrow, and the decision belongs in a clinical conversation.
Where the Research Goes From Here
The next several years will likely bring clearer answers about aspirin’s role in cancer care. Ongoing research into CHIP as a predictive biomarker, deeper understanding of how aspirin disrupts metastatic spread at the molecular level, and longer follow-up data from the ALASCCA and ASCOLT trials will all help refine who should and should not receive aspirin as part of cancer treatment. Researchers are also investigating whether aspirin has a role in cancers beyond colorectal — though the evidence there remains preliminary.
For now, the picture is both exciting and appropriately cautious. A drug that costs pennies a day has demonstrated meaningful anticancer effects in well-designed clinical trials, but only in specific patient populations defined by tumor genetics and disease stage. The days of asking whether aspirin prevents cancer are giving way to a more precise question: which patients, with which mutations, at which point in their treatment, stand to benefit most — and how do we identify them reliably before they ever swallow a pill.
Conclusion
The evidence supporting low-dose aspirin as part of cancer treatment has reached a tipping point for a specific group of patients. Colorectal cancer patients with PI3K pathway mutations now have two major randomized trials showing substantial reductions in recurrence risk — 51% in the ALASCCA trial and 44% in the ASCOLT trial. For patients with Lynch syndrome, longer-term data from the CAPP2 study adds further support. These findings are not hypothetical or preliminary. They are published in top-tier medical journals and are already influencing oncology practice.
But aspirin is not a universal cancer shield. It did not reduce cancer incidence in healthy older adults in the ASPREE trial, it did not help patients with colorectal liver metastases in the ASAC trial, and it carries real bleeding risks that must be weighed against potential benefits. For patients and families navigating cancer treatment — especially those also managing cognitive health concerns — the right move is not to self-prescribe but to bring these trial results into the conversation with your oncology team. Ask about tumor genetics. Ask about PI3K testing. And make the decision together, with full knowledge of both the promise and the limits of what a small daily aspirin can do.
Frequently Asked Questions
Does low-dose aspirin prevent all types of cancer?
No. The strongest clinical trial evidence is specific to colorectal cancer, particularly tumors with PI3K pathway mutations. The ASPREE trial found no reduction in overall cancer incidence among healthy older adults taking aspirin. Research into aspirin’s effects on other cancer types is ongoing but not yet conclusive.
How long do you need to take aspirin to get a cancer-prevention benefit?
For primary cancer prevention in at-risk populations, the USPSTF and the American College of Gastroenterology note that the full benefit requires at least 10 years of consistent use. In the adjuvant treatment setting — preventing recurrence after a cancer diagnosis — the ALASCCA and ASCOLT trials showed benefits over shorter follow-up periods.
Is aspirin safe for older adults with dementia who have cancer?
This depends entirely on the individual patient’s medical profile. Aspirin increases bleeding risk, including the risk of intracranial hemorrhage, which can worsen cognitive function. Any decision to add aspirin must be made by the treating oncologist in coordination with the patient’s other physicians, weighing tumor genetics, bleeding risk, and overall health.
What is a PI3K pathway mutation and how is it tested?
PI3K pathway mutations are genetic alterations in the tumor itself — not inherited mutations — that drive cancer cell growth. They are found in about 30% of colorectal cancers. Testing is performed on tumor tissue obtained during biopsy or surgery using molecular profiling. Not all pathology labs test for this automatically, so patients may need to request it.
Did the ASAC trial show that aspirin is harmful for cancer patients?
The ASAC trial found that aspirin did not improve survival for patients who had surgery for colorectal cancer liver metastases and was associated with increased serious adverse events. This does not mean aspirin is harmful for all cancer patients — it means its benefit is context-dependent and does not extend to the metastatic surgical setting studied in that trial.
What is CHIP and why does it matter for aspirin and cancer?
Clonal hematopoiesis of indeterminate potential is a condition where blood stem cells acquire mutations that give them a growth advantage. Research has identified CHIP as the strongest predictor of whether daily low-dose aspirin could help prevent cancer in healthy older adults. It represents a move toward personalized medicine, though CHIP testing is not yet part of routine clinical care.
